Oxford (OXFD) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Oxford Immunotec Reports Fourth Quarter and Full Year 2015 Financial Results
March 1, 2016 7:01 AM ESTFourth quarter revenue of $16.8 million increased 42% on a constant currency basis compared to prior year period2015 revenue of $62.8 million increased 33% on a constant currency basis compared to prior yearT-SPOT®.PRT assay made available in the United States as laboratory developed test (LDT)Gained CE Mark for the T-SPOT.PRT assay
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of... More
